Study of SCN-102
Latest Information Update: 17 Dec 2024
Price :
$35 *
At a glance
- Drugs Losartan (Primary)
- Indications Hypertension
- Focus Adverse reactions
- 17 Dec 2024 New trial record
- 10 Dec 2024 According to a Scienture media release, the New Drug Application (NDA) filed for SCN-102 is currently under review at the FDA.